Researchers in Italy have successfully treated the first patient with locally advanced pancreatic cancer using a new method called Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). This innovative treatment involves delivering alpha radiation directly into the tumor and is part of a clinical study at the University of Verona’s Pancreas Institute. The study is significant as it allows for two methods of delivering the treatment: endoscopic ultrasound and percutaneous delivery, making it accessible to a wider range of patients and healthcare providers.

For those concerned about aging and health, this development is particularly relevant. Pancreatic cancer is one of the deadliest cancers, with a very low five-year survival rate. In Italy alone, nearly 15,000 people die from this disease each year. The Alpha DaRT treatment aims to improve outcomes for patients who have limited options, especially those with tumors that cannot be surgically removed. By offering a new local intervention, this therapy could potentially enhance survival rates and quality of life for individuals facing this aggressive cancer.

The Alpha DaRT study is in its early stages, focusing on safety and feasibility with plans to enroll up to 15 patients. While the results from this initial treatment are promising, they are not yet definitive. The study will provide valuable data on how effective this treatment can be and whether it can be integrated into existing pancreatic cancer care protocols. As with all new therapies, more research is needed to confirm its benefits and safety in larger populations.

Source: globenewswire.com